What to know about Kyle Diamantas, the new acting FDA commissioner
The Guardian
Overall Assessment
The article presents a factually rich profile of Kyle Diamantas but frames him through a lens that emphasizes potential conflicts, ideological ties, and lack of medical credentials. Editorial choices highlight controversy over competence, with sourcing that is well-attributed but selectively critical. The tone leans skeptical, aligning with a watchdog stance rather than neutral introduction.
"defended a popular formula maker against claims of its product harming premature babies"
Loaded Language
Headline & Lead 75/100
The headline is neutral and appropriate, but the lead slightly frames Diamantas through a critical lens by foregrounding his legal defense of Abbott Labs in a harmful infant formula case.
✓ Balanced Reporting: The headline is straightforward and informative, accurately reflecting the article's focus on introducing the new acting FDA commissioner and his background.
"What to know about Kyle Diamantas, the new acting FDA commissioner"
✕ Framing By Emphasis: The lead emphasizes Diamantas’s corporate legal background and past representation of Abbott Laboratories, which may subtly cast doubt on his impartiality, though it is factually relevant.
"The new acting commissioner of the US Food and Drug Administration (FDA), who Donald Trump described as a “very talented person”, is a former corporate lawyer who previously defended a popular formula maker against claims of its product harming premature babies."
Language & Tone 60/100
The tone leans slightly negative, using loaded language and selective details to imply potential conflicts of interest and ideological alignment, rather than maintaining strict neutrality.
✕ Loaded Language: The phrase 'defended a popular formula maker against claims of its product harming premature babies' uses emotionally charged language that implies moral culpability, potentially biasing the reader against Diamantas.
"defended a popular formula maker against claims of its product harming premature babies"
✕ Editorializing: Describing Diamantas as 'apparently a close friend' of Donald Trump Jr. and including a hunting photo caption introduces personal details that may imply cronyism without explicit claim, injecting subtle judgment.
"Diamantas is also apparently a close friend of Donald Trump Jr, the president’s eldest son. A 2021 post on X from Mike Tussey, founder of hunting club Osceola Outdoors, includes a photo of the two men with the caption: “Don Jr. With his good friend Kyle Diamantas! Kyle’s first Osceola!”"
✕ Appeal To Emotion: Mention of a 'deadly gastrointestinal condition' and a $495m payout in the Abbott case evokes strong emotional response, potentially overshadowing neutral assessment of Diamantas’s qualifications.
"he defended Abbott Laboratories in a lawsuit accusing the company of failing to inform parents that its formula for premature infants increased the risk of a deadly gastrointestinal condition"
✕ Narrative Framing: The article repeatedly ties Diamantas to the 'Maha agenda' and figures like Paul Saladino and Gary Brecka, framing him within a controversial ideological movement rather than focusing solely on his regulatory role.
"Like many of his colleagues, Diamantas has frequented the Maha podcast circuit over the last year, spending time with Paul Saladino, a health influencer who has touted the benefits of a carnivore diet, as well as “biohacker” and longevity expert Gary Brecka."
Balance 65/100
Sourcing is strong in attribution but could improve by including more direct or balancing perspectives from Diamantas or his supporters.
✓ Proper Attribution: The article cites multiple sources including the FDA website, Washington Post, New York Times, Wall Street Journal, Vanity Fair, and Politico, providing clear attribution for key claims.
"according to the FDA’s website"
✓ Comprehensive Sourcing: The article draws on diverse sources including official statements, media reports, and public records, enhancing credibility.
✕ Cherry Picking: The article highlights Diamantas’s role in the Abbott case and his Maha connections but does not include direct input from him beyond a single interview quote, potentially skewing perception.
"The New York Times first reported Diamantas’s involvement in the case."
Completeness 70/100
The article offers significant background but omits key ethical context about recusal norms and could better balance ideological critique with policy substance.
✕ Omission: The article does not clarify whether Diamantas’s recusal from infant formula matters was mandatory or voluntary, nor does it assess the ethical norms around such recusals, leaving context incomplete.
"he followed a one-year recusal from infant formula matters after his 2025 appointment"
✕ Selective Coverage: Focus on Diamantas’s non-medical background and Maha ties may overemphasize ideological framing over his administrative experience or policy achievements.
"Diamantas, who holds a juris doctor from the University of Florida Levin College of Law, has no professional medical experience."
✓ Comprehensive Sourcing: The article provides substantial context on Diamantas’s career, legal background, policy impact (e.g., removal of artificial dyes), and organizational role, offering a multi-faceted profile.
"In a December 2025 interview with Politico, Diamantas said that his biggest achievement during the first year of the second Trump administration was the removal of petroleum-based artificial dyes from food products."
Portrays corporate actors in the food industry as untrustworthy due to past legal violations, with implications for regulatory capture
Loaded language and appeal to emotion are used to describe Diamantas’s defense of Abbott Labs in a case involving harm to infants, framing corporate behavior as ethically questionable and regulators as potentially compromised.
"he defended Abbott Laboratories in a lawsuit accusing the company of failing to inform parents that its formula for premature infants increased the risk of a deadly gastrointestinal condition"
Portrays the US government as potentially corrupt due to cronyism and lack of transparency in appointments
The article emphasizes personal connections (e.g., friendship with Donald Trump Jr.) and ideological alignment over merit, suggesting favoritism in leadership selection. Framing by emphasis and editorializing techniques highlight relationships rather than qualifications.
"Diamantas is also apparently a close friend of Donald Trump Jr, the president’s eldest son. A 2021 post on X from Mike Tussey, founder of hunting club Osceola Outdoors, includes a photo of the two men with the caption: “Don Jr. With his good friend Kyle Diamantas! Kyle’s first Osceola!”"
Undermines the legitimacy of public health leadership by highlighting lack of medical credentials and ideological alignment
Selective coverage and narrative framing emphasize Diamantas’s non-medical background and ties to fringe health influencers, casting doubt on the credibility of his authority in a scientific regulatory role.
"Diamantas, who holds a juris doctor from the University of Florida Levin College of Law, has no professional medical experience."
Frames public health leadership as compromised due to industry ties and ideological influence
Loaded language and narrative framing are used to associate Diamantas with controversial health ideologies (e.g., 'Maha agenda', carnivore diet advocates), implying his leadership may prioritize ideology over science-based policy.
"Like many of his colleagues, Diamantas has frequented the Maha podcast circuit over the last year, spending time with Paul Saladino, a health influencer who has touted the benefits of a carnivore diet, as well as “biohacker” and longevity expert Gary Brecka."
Highlights judicial outcomes that reflect harm caused by corporate actors, indirectly criticizing regulatory failure
Appeal to emotion technique used in describing the Abbott Laboratories case outcome, emphasizing the human cost and financial penalty to underscore regulatory shortcomings.
"In 2024, Abbott lost the lawsuit and was forced to pay $495m. A Missouri appellate court upheld the decision in May 2026, after an appeal from the manufacturer."
The article presents a factually rich profile of Kyle Diamantas but frames him through a lens that emphasizes potential conflicts, ideological ties, and lack of medical credentials. Editorial choices highlight controversy over competence, with sourcing that is well-attributed but selectively critical. The tone leans skeptical, aligning with a watchdog stance rather than neutral introduction.
Kyle Diamantas, previously the FDA deputy commissioner for food, has been named acting FDA commissioner following Marty Makary’s resignation. A lawyer by training, Diamantas has no medical background but has led food policy reforms, including updates to dietary guidelines and removal of artificial dyes. He previously worked at Jones Day, where he represented Abbott Laboratories in a formula lawsuit, and recused himself from related matters upon joining the FDA.
The Guardian — Lifestyle - Health
Based on the last 60 days of articles
The Guardian
